Skip to Content
Merck
CN

450960

Lutetium(III) chloride

anhydrous, powder, 99.99% trace metals basis

Synonym(s):

Lutetium chloride, Lutetium trichloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Linear Formula:
LuCl3
CAS Number:
10099-66-8
Molecular Weight:
281.33
NACRES:
NA.23
PubChem Substance ID:
24868595
UNSPSC Code:
12352302
EC Number:
233-240-1
MDL number:
MFCD00011099
Assay:
99.99% trace metals basis
Grade:
anhydrous
Form:
powder

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Lutetium(III) chloride, anhydrous, powder, 99.99% trace metals basis

InChI key

AEDROEGYZIARPU-UHFFFAOYSA-K

InChI

1S/3ClH.Lu/h3*1H;/q;;;+3/p-3

SMILES string

Cl[Lu](Cl)Cl

grade

anhydrous

assay

99.99% trace metals basis

form

powder

reaction suitability

core: lutetium
reagent type: catalyst

impurities

≤150.0 ppm Trace Rare Earth Analysis

mp

905 °C (lit.)

density

3.98 g/mL at 25 °C (lit.)

Quality Level

100

Related Categories

Application

Lutetium(III) chloride can be used:
  • As a precursor to synthesize chiral bridged lutetium catalyst for asymmetric hydroamination.
  • As a starting material to prepare doped lutetium oxide nanophosphors.
  • To fabricate scintillation detectors such as lutetium aluminum garnet (LuAG).

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000426805
0000426806
0000426806
0000426805
0000301323

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Development of new technologies for the manufacturing of nanocrystalline scintillation materials
Nikoloz V Jalabadze, et al.
IEEE transactions on nuclear science, 55, 1514-1522 (2008)
A Chiral-Bridged Aminotroponiminate Complex of Lutetium as Catalyst for the Asymmetric Hydroamination
Nils Meyer, et al.
Organometallics, 25, 4179-4182 (2006)
Swayamjeet Satapathy et al.
Nuclear medicine communications, 41(7), 629-635 (2020-05-07)
Peptide receptor radionuclide therapy (PRRT) has been shown to be useful in inoperable/metastatic medullary thyroid carcinoma (MTC). However, the role of concomitant PRRT and low-dose capecitabine therapy has not yet been studied in these patients. This study was conducted to
Swayamjeet Satapathy et al.
Clinical nuclear medicine, 45(9), e393-e399 (2020-07-01)
Advanced inoperable/metastatic neuroendocrine tumors (NETs) pose a therapeutic challenge with limited treatment options. Peptide receptor radionuclide therapy (PRRT), being specific in targeting the somatostatin receptors, is a promising and viable option in this setting. In this study, we intended to
Sanjay Kumar Saxena et al.
Cancer biotherapy & radiopharmaceuticals, 32(10), 364-370 (2017-12-22)
The primary objective of this investigation is the development of a strategy for the synthesis of polyhydroxamic acid (PHA)-grafted cellulose film, its characterization, and evaluation of its usefulness for the preparation of
View All Related Papers

Articles

Rare Earth Crisis—Supply/Demand Situation 2010–2015

Rare earth elements are vital in everyday life worldwide: catalysts in cars, colors in screens, magnets in electronics. Essential for modern living.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service